• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨大肝细胞癌伴出血的多学科综合治疗:一例报告并文献复习

Multidisciplinary comprehensive treatment of massive hepatocellular carcinoma with hemorrhage: A case report and review of literature.

作者信息

Kou Xian-Shuai, Li Fan-Fan, Meng Yun, Zhao Jian-Ming, Liu Sheng-Fen, Zhang Lan

机构信息

The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China.

Department of Thoracic Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China.

出版信息

World J Gastrointest Oncol. 2024 May 15;16(5):2225-2232. doi: 10.4251/wjgo.v16.i5.2225.

DOI:10.4251/wjgo.v16.i5.2225
PMID:38764847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11099427/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC), a major contributor to cancer-related deaths, is particularly prevalent in Asia, largely due to hepatitis B virus infection. Its prognosis is generally poor. This case report contributes to the medical literature by detailing a unique approach in treating a large HCC through multidisciplinary collaboration, particularly in patients with massive HCC complicated by ruptured bleeding, a scenario not extensively documented previously.

CASE SUMMARY

The patient presented with large HCC complicated by intratumoral bleeding. Treatment involved a multidisciplinary approach, providing individualized care. The strategy included drug-eluting bead transarterial chemoembolization, sorafenib-targeted therapy, laparoscopic partial hepatectomy, and standardized sintilimab monoclonal antibody therapy. Six months after treatment, the patient achieved complete radiological remission, with significant symptom relief. Imaging studies showed no lesions or recurrence, and clinical assessments confirmed complete remission. This report is notable as possibly the first documented case of successfully treating such complex HCC conditions through integrated multidisciplinary efforts, offering new insights and a reference for future similar cases.

CONCLUSION

This study demonstrated effective multidisciplinary treatment for massive HCC with intratumoral bleeding, providing insights for future similar cases.

摘要

背景

肝细胞癌(HCC)是癌症相关死亡的主要原因之一,在亚洲尤为普遍,主要归因于乙型肝炎病毒感染。其预后通常较差。本病例报告通过详细阐述一种多学科协作治疗大型HCC的独特方法,为医学文献做出了贡献,特别是对于伴有破裂出血的巨大HCC患者,这一情况此前未被广泛记录。

病例摘要

该患者患有大型HCC并伴有瘤内出血。治疗采用多学科方法,提供个性化护理。治疗策略包括载药微球经动脉化疗栓塞、索拉非尼靶向治疗、腹腔镜部分肝切除术以及标准化的信迪利单抗单克隆抗体治疗。治疗六个月后,患者实现了影像学完全缓解,症状明显缓解。影像学检查未发现病变或复发,临床评估证实完全缓解。本报告值得注意,因为它可能是首例通过综合多学科努力成功治疗此类复杂HCC病例的记录,为未来类似病例提供了新的见解和参考。

结论

本研究证明了对伴有瘤内出血的巨大HCC进行多学科治疗的有效性,为未来类似病例提供了见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/815b/11099427/22be3d937f01/WJGO-16-2225-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/815b/11099427/6e36cc5bbeb3/WJGO-16-2225-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/815b/11099427/22be3d937f01/WJGO-16-2225-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/815b/11099427/6e36cc5bbeb3/WJGO-16-2225-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/815b/11099427/22be3d937f01/WJGO-16-2225-g002.jpg

相似文献

1
Multidisciplinary comprehensive treatment of massive hepatocellular carcinoma with hemorrhage: A case report and review of literature.巨大肝细胞癌伴出血的多学科综合治疗:一例报告并文献复习
World J Gastrointest Oncol. 2024 May 15;16(5):2225-2232. doi: 10.4251/wjgo.v16.i5.2225.
2
Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection.手术切除后复发性肝细胞癌的非手术多学科治疗方法
Hepat Oncol. 2015 Jan;2(1):29-38. doi: 10.2217/hep.14.31. Epub 2015 Jan 12.
3
Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report.信迪利单抗联合索拉非尼治疗转移性肝细胞癌并实现完全缓解后行肝切除术:1例病例报告
Front Oncol. 2024 Feb 6;14:1355798. doi: 10.3389/fonc.2024.1355798. eCollection 2024.
4
The importance of a multidisciplinary approach to hepatocellular carcinoma.多学科方法对肝细胞癌的重要性。
J Multidiscip Healthc. 2017 Mar 20;10:95-100. doi: 10.2147/JMDH.S128629. eCollection 2017.
5
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.索拉非尼为基础的多学科治疗 Vp4 肝细胞癌的长期生存:病例报告。
Clin J Gastroenterol. 2022 Oct;15(5):953-959. doi: 10.1007/s12328-022-01667-9. Epub 2022 Jun 30.
6
Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.经动脉药物洗脱微球化疗栓塞治疗肝细胞癌后延迟性瘤内出血
Case Rep Oncol. 2014 Nov 1;7(3):739-45. doi: 10.1159/000369005. eCollection 2014 Sep.
7
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.经动脉化疗栓塞术联合仑伐替尼对比经动脉化疗栓塞术联合索拉非尼作为伴门静脉癌栓的肝细胞癌一线治疗的前瞻性随机研究。
Cancer. 2021 Oct 15;127(20):3782-3793. doi: 10.1002/cncr.33677. Epub 2021 Jul 8.
8
Complete response by patients with advanced hepatocellular carcinoma after combination immune/targeted therapy and transarterial chemoembolization: two case reports and literature review.晚期肝细胞癌患者在免疫/靶向联合治疗及经动脉化疗栓塞后的完全缓解:两例病例报告及文献综述
Transl Cancer Res. 2022 Aug;11(8):2973-2984. doi: 10.21037/tcr-21-2691.
9
Multidisciplinary approach for multifocal, bilobar hepatocellular carcinoma: A case report and literature review.多学科方法治疗多灶性、双叶肝细胞癌:一例报告及文献综述
World J Hepatol. 2019 Jan 27;11(1):119-126. doi: 10.4254/wjh.v11.i1.119.
10
Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.晚期肝细胞癌:一家地区癌症中心48例病例的经验
Indian J Cancer. 2017 Jul-Sep;54(3):526-529. doi: 10.4103/ijc.IJC_373_17.

本文引用的文献

1
Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology.肝细胞癌:分子分类和精准肿瘤学的过去、现在的挑战与进展。
Int J Mol Sci. 2023 Aug 26;24(17):13274. doi: 10.3390/ijms241713274.
2
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.系统治疗晚期肝细胞癌指南推荐的批判性评价:综述。
JAMA Oncol. 2024 Mar 1;10(3):395-404. doi: 10.1001/jamaoncol.2023.2677.
3
Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
药物洗脱微球经动脉化疗栓塞术与传统经动脉化疗栓塞术治疗伴有主门静脉癌栓的晚期 HCC 患者的安全性、疗效和生存。
Cancer Imaging. 2023 Jul 22;23(1):70. doi: 10.1186/s40644-023-00581-8.
4
Surgical resection for large hepatocellular carcinoma and those beyond BCLC: systematic review with proposed management algorithm.手术切除治疗大肝癌和巴塞罗那分期 C 期肝癌以外的肝癌:系统综述与提出的治疗方案算法。
Langenbecks Arch Surg. 2023 Apr 12;408(1):144. doi: 10.1007/s00423-023-02881-w.
5
Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives.晚期肝细胞癌的系统治疗:现状与展望
Cancers (Basel). 2023 Mar 9;15(6):1680. doi: 10.3390/cancers15061680.
6
The current trends in the health burden of primary liver cancer across the globe.全球原发性肝癌健康负担的当前趋势。
Clin Mol Hepatol. 2023 Apr;29(2):358-362. doi: 10.3350/cmh.2023.0092. Epub 2023 Mar 14.
7
Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.信迪利单抗联合乐伐替尼用于中/局部晚期肝细胞癌的转化治疗:一项2期研究。
Front Oncol. 2023 Feb 16;13:1115109. doi: 10.3389/fonc.2023.1115109. eCollection 2023.
8
Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma.自发性破裂肝细胞癌患者生存预后的预测因素。
Hepatol Int. 2022 Dec;16(6):1330-1338. doi: 10.1007/s12072-022-10403-x. Epub 2022 Aug 25.
9
Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma.TACE 联合仑伐替尼和信迪利单抗治疗中期肝细胞癌的疗效研究。
Dis Markers. 2022 Jul 6;2022:6957580. doi: 10.1155/2022/6957580. eCollection 2022.
10
[Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)].《肝细胞癌诊疗规范(2022年版)》
Zhonghua Gan Zang Bing Za Zhi. 2022 Apr 20;30(4):367-388. doi: 10.3760/cma.j.cn501113-20220413-00193.